SCHEMBL5213791

SCHEMBL5213791

COc1cc2[nH]c(C)c(CC(=O)Nc3ccccc3C(=O)O)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.52
▸ CHEK1 O14757 1/20 0.48
▸ PIM1 P11309 1/20 0.48
▸ MAPK8 P45983 1/20 0.48
▸ CLK4 Q9HAZ1 1/20 0.48
▸ KDM4E B2RXH2 6/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ GAA P10253 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ HCAR2 Q8TDS4 1/20 0.46
▸ CYP3A4 P08684 3/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ HPGD P15428 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TP53 P04637 2/20 0.44
▸ HIF1A Q16665 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207058 0.88 MAPT (0.46) POLBKDM4EALDH1A1GAACYP3A4
SCHEMBL5206552 0.86 AKR1C2 (0.63) POLBKDM4EALDH1A1HSD17B10HCAR2
SCHEMBL11338063 0.76 AKR1C2 (0.66) POLBKDM4EALDH1A1GAAMEN1
SCHEMBL5205838 0.75 AKR1C2 (0.61) POLBKDM4EALDH1A1GAAMEN1
SCHEMBL5214528 0.75 AKR1C2 (0.61) POLBKDM4EALDH1A1GAAMEN1
SCHEMBL5211697 0.75 MAPT (0.55) POLBKDM4EALDH1A1GAACYP3A4
SCHEMBL28618230 0.75 CHEK1 (0.63) POLBCHEK1PIM1MAPK8CLK4
SCHEMBL5208570 0.73 AKR1C2 (0.59) POLBKDM4EALDH1A1GAACYP3A4
SCHEMBL5208935 0.73 MEN1 (0.62) POLBKDM4EALDH1A1MEN1KMT2A
SCHEMBL5209238 0.73 AKR1C2 (0.59) POLBKDM4EALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US claimed
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US disclosed
EP-1343757-B1 INDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2007-02-14 — — EP disclosed
US-20040092569-A1 Indole derivatives GLAXO GROUP LIMITED (GB) 2004-05-13 — — US disclosed
EP-1343757-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-09-17 — — EP disclosed
WO-2002050031-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092569-A1 Indole derivatives PTGER4, PTGER1, TRPV4 POLB 4642/4885CHEK1 4504/4885PIM1 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback